Dr. Xiaofeng Liu studied at Peking University and graduated as Ph.D. in 2017. He then joined the research group of Prof. Xing at Peking University Cancer Hospital & Institute. After two-year postdoctoral fellowship, he obtained the position of an Associate Professor at PUCHI. The research in his laboratory is aimed at developing the potential targets and applying them to improve strategy for treating HCC. They employ diverse methods including CRISPR/Cas9-mediated genome editing, High-throughput sequencing, proteomics, and traditional biochemical methods. He has published more than 20 research articles in SCI (E) journals in recent years.